<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290433</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0004</org_study_id>
    <secondary_id>NCI-2010-00445</secondary_id>
    <nct_id>NCT00290433</nct_id>
  </id_info>
  <brief_title>Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if treatment with two types of&#xD;
      chemotherapy combinations can help to control peripheral T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All of the drugs used in this study are commonly used in the treatment of cancer. However,&#xD;
      using these drugs in combination is investigational.&#xD;
&#xD;
      During treatment, you will be given two different cycles of chemotherapy, which will be&#xD;
      alternated every 21 days.&#xD;
&#xD;
      For Cycle 1, cyclophosphamide will be given by vein two times a day on Days 1,2, and 3. Each&#xD;
      dose will take around 3 hours to give. Mesna will be given by vein nonstop over Days 1&#xD;
      through 3. Pegylated liposomal doxorubicin will be given by vein over 1 hour on Day 2.&#xD;
      Vincristine will be given by vein on Days 4 and 11. Dexamethasone will be given by mouth on&#xD;
      Days 1 through 4 and 11 through 14. Other drugs will be given before, during, and after&#xD;
      chemotherapy to help decrease the risk of developing side effects. These drugs may be given&#xD;
      by mouth or by injection.&#xD;
&#xD;
      For Cycle 2, methotrexate will be given by vein over 2 hours on Day 1 and over 22 hours on&#xD;
      day 1. Cytarabine will be given by vein twice a day on Days 2 and 3. Each dose will take&#xD;
      about 2 hours to give. Other drugs will be given before, during, and after treatment to help&#xD;
      decrease the risk of developing side effects. These drugs may be given by mouth or by&#xD;
      injection.&#xD;
&#xD;
      To help increase the blood counts and help decrease the risk of developing infections, your&#xD;
      doctor may decide that treatment with filgrastim is necessary. Filgrastim may be given as&#xD;
      once-a-day injections under the skin starting 24 hours after the end of Day 4 vincristine&#xD;
      (Cycle 1) and starting 24 hours after the end of Cytarabine (Cycle 2). Your blood counts will&#xD;
      be monitored and filgrastim is stopped when the levels become normal.&#xD;
&#xD;
      Cycles 1 and 2 will be alternated every 21 days. Both Cycles 1 and 2 can be given on an&#xD;
      outpatient basis if your physician authorizes it. However, if your serum creatinine (blood&#xD;
      test) reaches a certain level, Cycle 2 should be given on an inpatient basis.&#xD;
&#xD;
      Depending on how the disease responds, treatment may be stopped after 2,4, or 6 cycles.&#xD;
      However, treatment may continue for up to 8 cycles.&#xD;
&#xD;
      During treatment, you will have around 2-3 tablespoons of blood collected at least once a&#xD;
      week for routine tests.&#xD;
&#xD;
      After every 2 cycles, tumors will be measured using x-rays or other scans (CT, MRI, etc.) and&#xD;
      bone marrow samples will be taken. Heart scans or heart function tests may also be needed if&#xD;
      you doctor feels it is necessary.&#xD;
&#xD;
      If the disease gets worse or you experience any intolerable side effects, you will be taken&#xD;
      off the study and your doctor will discuss other treatment options with you.&#xD;
&#xD;
      After the last cycle of chemotherapy, you will have follow-up exams scheduled. During these&#xD;
      exams, you will have a chest x-ray and CT scans of the chest, abdomen (stomach) and pelvis&#xD;
      (waist area), and PET scan. You will have blood collected (2-3 tablespoons) for routine&#xD;
      tests. If your doctor feels it is necessary, you may also have a sample of bone marrow&#xD;
      collected. You may choose to have long-term follow-up exams at M. D. Anderson or with your&#xD;
      local physician.&#xD;
&#xD;
      This is an investigational study. All of the study drugs are approved by the FDA for cancer&#xD;
      treatment and are commercially available. However, the use of the drugs in combination is&#xD;
      experimental. Up to 55 participants will take part in this study. All will be enrolled at M.&#xD;
      D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 Year Progression-Free Survival Rate</measure>
    <time_frame>From registration to disease progression or death, up to 3 years</time_frame>
    <description>Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.&#xD;
Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil</intervention_name>
    <description>Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.</description>
    <arm_group_label>HCVIDDOXIL Regimen</arm_group_label>
    <other_name>Pegylated Liposomal Doxorubicin</other_name>
    <other_name>Doxorubicin hydrochloride (lipsomal)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of previously untreated T-cell Non Hodgkin's Lymphomas and NK&#xD;
             lymphomas, with the exception of cluster of differentiation antigen 30 (CD30+) alk1+&#xD;
             T-anaplastic large cell lymphoma (ALCL). Patients with skin involvement alone are also&#xD;
             excluded. For patients with skin involvement as part of systemic disease, prior&#xD;
             topical treatment only is allowed.&#xD;
&#xD;
          2. Patients with a performance status of 3 or less (Zubrod Scale - see Appendix D).&#xD;
&#xD;
          3. Serum bilirubin &lt;/= 1.5 mg/dl and serum creatinine &lt;/= 2.0 mg/dl unless due to&#xD;
             lymphoma; Absolute neutrophil count (ANC) &gt;/= 1000 mm^3 and platelets &gt;/= 100,000 mm^3&#xD;
             unless due to lymphoma.&#xD;
&#xD;
          4. Cardiac ejection fraction 50% or greater by multigated radionuclide angiography (MUGA)&#xD;
             or echocardiogram.&#xD;
&#xD;
          5. Ages 18 and older.&#xD;
&#xD;
          6. Patients must be willing to receive transfusions of blood products.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with CD30+ alk1+ T-anaplastic large cell lymphoma (ALCL) or patients with&#xD;
             skin involvement alone.&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. HIV positive serology&#xD;
&#xD;
          4. Central nervous system (CNS) involvement&#xD;
&#xD;
          5. Co-morbid medical, such as Child's Class C liver cirrhosis, end-stage renal disease,&#xD;
             and symptomatic congestive heart failure, or psychiatric illnesses that preclude&#xD;
             treatment with intense dose chemotherapy as determined by the primary investigator&#xD;
&#xD;
          6. Concurrent or previous malignancy whose prognosis is poor (&lt;90% probability of&#xD;
             survival at 5 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuhiro Oki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <results_reference>
    <citation>Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov;171(4):509-16. doi: 10.1111/bjh.13628. Epub 2015 Aug 10.</citation>
    <PMID>26260306</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>July 27, 2016</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Peripheral T Cell</keyword>
  <keyword>HCVIDDOXIL Regimen</keyword>
  <keyword>ARA-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Pegylated Liposomal Doxorubicin</keyword>
  <keyword>Doxorubicin hydrochloride</keyword>
  <keyword>Doxil</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Mesna</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Vincristine</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: September 17, 2003 to May 8, 2009. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 55 participants registered, two participants were found not to be eligible prior to start of study therefore are excluded from trial details.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HCVIDDOXIL Regimen</title>
          <description>Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.&#xD;
Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Congestive Heart Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplant in CR</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated Infection/Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HCVIDDOXIL Regimen</title>
          <description>Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.&#xD;
Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="20" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>3 Year Progression-Free Survival Rate</title>
        <description>Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause.</description>
        <time_frame>From registration to disease progression or death, up to 3 years</time_frame>
        <population>Of the 53 participants, *6 participants* were not evaluable for response due to either no measurable disease (1) or early departure from study for adverse events (5)</population>
        <group_list>
          <group group_id="O1">
            <title>HCVIDDOXIL Regimen</title>
            <description>Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.&#xD;
Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>3 Year Progression-Free Survival Rate</title>
          <description>Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause.</description>
          <population>Of the 53 participants, *6 participants* were not evaluable for response due to either no measurable disease (1) or early departure from study for adverse events (5)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="18" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed from the initiation of the regimen through the end of the chemotherapy cycle, up to 3 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HCVIDDOXIL Regimen</title>
          <description>Cycle 1: Cyclophosphamide 300 mg/m^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m^2 continuous IV Days 1-3. Doxil 25 mg/m^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.&#xD;
Cycle 2: Methotrexate 200 mg/m^2 over 2 hours on Day 1 and 800 mg/m^2 over 22 hours on day 1. Cytarabine 3 Gm/m^2 IV twice a day on Days 2 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>massive cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Toxicities</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious Disease</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Flowers/Chair, Lymphoma-Myeloma</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-745-6095</phone>
      <email>crflowers@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

